
    
      Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are
      hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to
      receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered
      via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14
      days and will be followed up for up to 90 days after completion of study medication. Study
      data will be collected from patients daily, as per the study schedule.
    
  